Financial Performance - For Q1 2025, Sphere 3D reported revenues of $2.8 million, a decrease of 59.4% from $6.9 million in Q1 2024, primarily due to 22% of mining machines being taken offline[103]. - The direct cost of revenues for Q1 2025 was $2.2 million, down 48.8% from $4.3 million in Q1 2024, attributed to lower hosting fees and the transition to newer generation machines[104]. - The company experienced a loss on disposal of property and equipment of $0.8 million in Q1 2025, compared to nil in Q1 2024[107]. - General and administrative expenses decreased to $3.2 million in Q1 2025 from $3.5 million in Q1 2024, primarily due to reduced share-based compensation and employee-related expenses[105]. - For the three months ended March 31, 2025, the company reported a net cash used in operating activities of $4.078 million, compared to $58,000 in the same period of 2024[116]. - The company experienced a net loss of $8.8 million during the first three months of 2025, which was offset by $6.3 million in non-cash items[116]. Mining Operations - Sphere 3D mined 30.5 Bitcoin in Q1 2025, a 5.0% decrease from 32.1 Bitcoin in Q4 2024, due to strategic changes in operations[97]. - As of March 31, 2025, Sphere 3D owned approximately 13,000 miners, with 6,400 in service and a total hashrate capacity of 0.82 EH/s[97]. - The company anticipates achieving approximately 1.5 EH/s of total hashrate in operation during 2025 based on existing operations and expected miner deployments[97]. - The company plans to lower mining costs and refresh its mining fleet to enhance efficiency[113]. Cash and Liquidity - As of March 31, 2025, Sphere 3D had cash and cash equivalents of $2.8 million, down from $5.4 million at December 31, 2024[110]. - Cash on hand may not be sufficient for the company to continue operations within 12 months if additional funding is not raised[113]. - The company received $2.1 million from the sale of Bitcoin during the first three months of 2025[117]. - The company provided $0.1 million of net proceeds from financing activities in the first three months of 2025[118]. Future Outlook and Funding - Sphere 3D entered into an At-the-Market Offering Program with a potential aggregate offering price of up to $8.0 million for working capital and corporate strategy purposes[111]. - The company expects working capital needs to increase in the future as operations expand[113]. - Significant risks include potential shortfalls in projected mining earnings and increases in operating costs, which could impact funding access[114]. Share Issuance - The company issued 210,448 common shares for approximately $0.1 million net proceeds under the AGP Agreement[112]. Other Information - As of March 31, 2025, the company had no standby letters of credit outstanding[119]. - The fair value of Bitcoin held by Sphere 3D as of March 31, 2025, was approximately $1.9 million[98].

Financial Performance - Net loss attributable to common shareholders for the three months ended March 31, 2025, was $3,602,698, compared to a net loss of $5,496,273 for the same period in 2024, reflecting a reduction of approximately 34.4%[12] - The company reported a net loss of $3.446 billion for the quarter[16] - The net loss for the six months ended March 31, 2025, was $8,244,544, compared to a net loss of $8,844,288 for the same period in 2024, indicating a decrease in losses by approximately 6.8%[20] - The net loss for the three months ended March 31, 2025, was $3,579,000, a 33.7% improvement compared to a net loss of $5,398,000 for the same period in 2024[198] - The net loss for the six months ended March 31, 2025, was $8,245,000, a 6.8% improvement compared to a net loss of $8,844,000 for the same period in 2024[206] Assets and Liabilities - Total current assets decreased to $443,913 in 2025 from $3,110,755 in 2024, representing a decline of approximately 86.7%[9] - Total liabilities increased to $6,807,734 in 2025 from $5,820,629 in 2024, marking an increase of about 17%[9] - Total stockholders' deficit increased to $(5,883,549) in 2025 from $(2,156,201) in 2024, representing a decline of approximately 172.5%[9] - As of December 31, the balance sheet showed total assets of $17.858 billion, with liabilities of $16.161 billion[16] - The balance as of March 31 shows a total of $17.858 billion in assets, indicating stability in financial position[16] Expenses - Research and development expenses for the six months ended March 31, 2025, were $1,220,309, down from $3,661,633 in 2024, indicating a decrease of about 66.7%[12] - Selling, general and administrative expenses for the three months ended March 31, 2025, were $1,789,315, compared to $2,550,848 in 2024, a decrease of approximately 29.9%[12] - Interest expense for the six months ended March 31, 2025, was $2,557,844, compared to $740,251 in 2024, an increase of approximately 245.5%[12] - The company incurred advertising and marketing costs of $10,000 for the three months ended March 31, 2025, compared to $58,866 in the same period of the previous year[42] - The total depreciation expense for the three months ended March 31, 2025, was $7,162, compared to $19,643 for the same period in 2024[59] Stock and Equity - The basic and diluted loss per share for the three months ended March 31, 2025, was $(1.24), compared to $(2.69) for the same period in 2024, showing an improvement of about 54.9%[12] - The weighted average shares of common stock outstanding for the three months ended March 31, 2025, were 2,909,985, compared to 2,044,153 in 2024, an increase of approximately 42.3%[12] - The company issued options totaling 6.616 million shares, indicating ongoing employee incentives[16] - The total stock expenses were reported at $9.860 million, highlighting the company's commitment to shareholder value[16] - The company has a total of 5.594 million warrants outstanding, which could impact future equity dilution[16] Strategic Initiatives - The company is focusing on market expansion and new product development to drive future growth[16] - The company is exploring strategic acquisitions to enhance its market position and product offerings[16] - Know Labs announced the development of the KnowU™ non-invasive wearable continuous glucose monitor prototype, which is currently undergoing internal clinical testing[128] - The company is in discussions with potential biopharma, medical device, and consumer electronics partners regarding joint development agreements to accelerate development and commercial launch[159] - The KTL initiative aims to license Know Labs' intellectual property to corporate partners and academic institutions, fostering innovation across various industries[157] Compliance and Future Outlook - Future guidance suggests a cautious outlook due to current market conditions and competitive pressures[16] - The company has substantial doubt about its ability to continue as a going concern, as it may require additional financing to support its operations[34] - The NYSE American lifted the trading suspension of the company's common stock on March 5, 2025, after the stock traded above the low selling price threshold[189] - The company has a target completion date of March 27, 2026, to regain compliance with the NYSE American's continued listing standards[190] - Know Labs received notification from the NYSE American regarding non-compliance with minimum stockholders' equity requirements, and submitted a plan to regain compliance by March 27, 2026[186] Research and Development - The Company is focused on the development of a non-invasive blood glucose monitoring device, with a working prototype launched in the previous fiscal year[28] - The internal clinical research study showed a Mean Absolute Relative Difference (MARD) of 11.1% in measuring blood glucose levels using the proprietary RF dielectric sensor[139] - The sensor technology has demonstrated a high degree of correlation with leading continuous glucose monitors, providing a non-invasive alternative[138] - A study indicated that the technology achieved 93.37% accuracy in classifying glycemic status compared to venous blood glucose values[145] - The company is focused on refining its algorithms and expanding testing to ensure accurate glucose value estimation across diverse populations[147]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 001-39248 The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware 84-3562323 (State ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _______________________ Commission file number: 001-37544 ARMATA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (Addre ...

```markdown PART I - FINANCIAL INFORMATION [Condensed Consolidated Financial Statements (unaudited)](index=5&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements%20(unaudited)) This section presents unaudited condensed financial statements for Q1 2025 and 2024, detailing increased net loss, a shift to shareholders' deficit, and a going concern disclosure [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Precigen's balance sheet as of March 31, 2025, reflects decreased assets, increased liabilities from warrant revaluation, and a shift to a shareholders' deficit Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | March 31, 2025 | December 31, 2024 | Change | | :--- | :--- | :--- | :--- | | Cash and cash equivalents | $6,058 | $29,517 | ($23,459) | | Short-term investments | $74,184 | $68,393 | $5,791 | | **Total Assets** | **$128,787** | **$145,266** | **($16,479)** | | Warrant liabilities | $83,018 | $50,537 | $32,481 | | **Total Liabilities** | **$113,329** | **$78,535** | **$34,794** | | **Total Shareholders' (Deficit) Equity** | **($14,060)** | **$38,513** | **($52,573)** | [Condensed Consolidated Statements of Operations](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Q1 2025 operations show increased revenues and narrowed operating loss, but a significant non-cash warrant liability expense resulted in a substantial net loss increase Q1 2025 vs Q1 2024 Statement of Operations (in thousands, except per share data) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Total Revenues | $1,341 | $1,065 | | Research and development | $10,478 | $14,249 | | Selling, general and administrative | $12,359 | $10,151 | | Operating loss | ($22,596) | ($24,410) | | Change in fair value of warrant liabilities | ($32,481) | $0 | | **Net loss** | **($54,153)** | **($23,738)** | | **Net loss per share, basic and diluted** | **($0.18)** | **($0.10)** | [Condensed Consolidated Statements of Cash Flows](index=10&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Q1 2025 cash flows indicate increased cash used in operations and a reversal in investing activities, leading to a significant overall decrease in cash and cash equivalents Cash Flow Summary (in thousands) | Activity | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | ($16,325) | ($14,090) | | Net cash (used in) provided by investing activities | ($6,457) | $24,045 | | Net cash used in financing activities | ($679) | $0 | | **Net (decrease) increase in cash** | **($23,459)** | **$9,895** | [Notes to the Condensed Consolidated Financial Statements](index=12&type=section&id=Notes%20to%20the%20Condensed%20Consolidated%20Financial%20Statements) The notes detail accounting policies, PRGN-2012's PDUFA date, substantial doubt about going concern, warrant liability re-measurement, and segment realignment - The company's lead product candidate, **PRGN-2012**, has been granted **priority review** by the FDA with a PDUFA target action date of **August 27, 2025**[35](index=35&type=chunk) - Management has concluded there is **substantial doubt about the Company's ability to continue as a going concern**, as its current cash and investments are **not sufficient to fund planned operations for one year**. This analysis excludes potential revenue from PRGN-2012, which is not yet approved[42](index=42&type=chunk)[44](index=44&type=chunk) - The company recorded a **$32.5 million expense** due to the **change in fair value of warrant liabilities**, driven by an increase in the company's stock price and other factors[80](index=80&type=chunk) - Effective Q1 2025, the company realigned its operations into a **single operating segment** to streamline operations and focus on the potential commercial launch of PRGN-2012[123](index=123&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=27&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the strategic shift to prioritize PRGN-2012, detailing Q1 2025 financial results, including R&D and SG&A changes, warrant liability impact, and reiterating the going concern issue [Overview](index=27&type=section&id=Overview) Precigen, a clinical-stage biopharmaceutical company, strategically prioritized its pipeline on PRGN-2012 for RRP, which received FDA priority review with an August 2025 PDUFA date, while pausing other clinical trials - The company has **strategically prioritized** its pipeline to focus resources on the potential commercialization of its lead program, **PRGN-2012**[133](index=133&type=chunk) - The FDA granted **priority review** to the **PRGN-2012 Biologics License Application (BLA)** for RRP, with a PDUFA target action date of **August 27, 2025**[134](index=134&type=chunk)[137](index=137&type=chunk) - As part of the restructuring, enrollment has been **paused** for the **PRGN-3005 and PRGN-3007 UltraCAR-T clinical trials** to minimize spending and focus on partnerships[132](index=132&type=chunk)[133](index=133&type=chunk) [Results of Operations](index=31&type=section&id=Results%20of%20operations) Q1 2025 results show a 26% revenue increase, a 27% decrease in R&D expenses, a 22% increase in SG&A expenses, and a significant net loss increase due to a non-cash warrant liability charge Comparison of Operations for the Three Months Ended March 31 (in thousands) | Item | 2025 | 2024 | $ Change | % Change | | :--- | :--- | :--- | :--- | :--- | | Total revenues | $1,341 | $1,065 | $276 | 25.9% | | Research and development | $10,478 | $14,249 | ($3,771) | (26.5)% | | Selling, general and administrative | $12,359 | $10,151 | $2,208 | 21.8% | | Operating loss | ($22,596) | ($24,410) | $1,814 | (7.4)% | | Net loss | ($54,153) | ($23,738) | ($30,415) | 128.1% | - R&D expenses **decreased by $3.8 million**, mainly due to the **closure of ActoBio operations** and **reduced headcount** following the 2024 strategic prioritization[161](index=161&type=chunk) - SG&A expenses **increased by $2.2 million**, primarily driven by costs for **PRGN-2012 commercial readiness**[162](index=162&type=chunk) - The **significant increase in net loss** was primarily caused by a **non-cash charge of $32.5 million** for the **change in fair value of warrant liabilities**, influenced by an increase in the company's stock price[163](index=163&type=chunk) [Liquidity and Capital Resources](index=32&type=section&id=Liquidity%20and%20capital%20resources) As of March 31, 2025, the company had $81.0 million in cash and investments, but despite recent capital raises, management concluded existing funds are insufficient for one year, raising substantial doubt about its going concern ability - As of March 31, 2025, the company had **$6.1 million** in cash and cash equivalents and **$74.9 million** in investments[164](index=164&type=chunk) - Recent financing includes a public offering in August 2024 (net proceeds **$30.9M**) and a private placement of preferred stock and warrants in December 2024 (net proceeds **~$78.5M**)[165](index=165&type=chunk)[166](index=166&type=chunk) - Management states that current cash projections, excluding potential but uncertain revenue from PRGN-2012, are **not sufficient to fund operations for at least one year**, which raises **substantial doubt about the company's ability to continue as a going concern**[176](index=176&type=chunk) - Future capital needs will be financed through a combination of **equity/debt offerings, strategic alliances, and potential product revenue**. The ability to continue as a going concern depends on **successfully commercializing PRGN-2012 or raising additional capital**[173](index=173&type=chunk)[177](index=177&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=36&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risk is interest rate risk on its $81.0 million in cash and investments, with management believing a 100 basis point rate increase would not materially affect fair value - The company's market risk is primarily related to **interest rate fluctuations** on its **$81.0 million** of cash, cash equivalents, and investments[186](index=186&type=chunk) - Management believes a hypothetical **100 basis point change** in interest rates would **not have a material effect** on the fair value of its financial instruments[186](index=186&type=chunk) [Controls and Procedures](index=36&type=section&id=Item%204.%20Controls%20and%20Procedures) As of March 31, 2025, the CEO and CFO concluded that disclosure controls and procedures are effective, with no material changes to internal control over financial reporting during the quarter - Management, including the CEO and CFO, concluded that the company's disclosure controls and procedures were **effective** as of March 31, 2025[187](index=187&type=chunk) - **No material changes** to the company's internal control over financial reporting occurred during the first quarter of 2025[188](index=188&type=chunk) PART II - OTHER INFORMATION [Legal Proceedings](index=37&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in various legal matters, including a derivative shareholder action, but does not anticipate a material adverse effect, with a $3.2 million indemnification accrual remaining - The company is involved in a **derivative shareholder action** (Wright v. Alvarez et al.) and a **shareholder lawsuit** demanding inspection of books and records (Kent v. Precigen, Inc.), both related to historical disclosures[119](index=119&type=chunk) - As of March 31, 2025, an **indemnification accrual of $3.213 million** remains related to the sale of Trans Ova[121](index=121&type=chunk) - Management does **not currently believe** that ongoing legal matters will have a **material adverse effect** on the company's financial condition or operations[191](index=191&type=chunk) [Risk Factors](index=37&type=page&id=Item%201A.%20Risk%20Factors) No material updates or changes to the company's risk factors have occurred since the filing of its Annual Report on Form 10-K for the year ended December 31, 2024 - **No material updates or changes** to the company's risk factors have occurred since the filing of the Annual Report for the year ended December 31, 2024[193](index=193&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=37&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) None - **None**[195](index=195&type=chunk) [Defaults on Senior Securities](index=37&type=section&id=Item%203.%20Defaults%20on%20Senior%20Securities) None - **None**[196](index=196&type=chunk) [Mine Safety Disclosures](index=37&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) Not applicable - **Not applicable**[197](index=197&type=chunk) [Other Information](index=37&type=section&id=Item%205.%20Other%20Information) None - **None**[198](index=198&type=chunk) [Exhibits](index=38&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including CEO and CFO certifications required by the Sarbanes-Oxley Act and the Interactive Data File (XBRL) - Exhibits include **CEO and CFO certifications** pursuant to **Sarbanes-Oxley Act Sections 302 and 906**[199](index=199&type=chunk) ```

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (State or other jurisdiction of incorporation or organization) 1311 (Primary Standard Industrial Classification Code Number) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38150 KALA BIO, Inc. (Exact name of registrant as specified in its charter) Delaware 27-0604595 (State or other jurisdict ...

Financial Performance - The net loss for the three months ended March 31, 2025, was $32.0 million, compared to a net loss of $29.5 million for the same period in 2024, indicating an increase in loss of about 8.3%[19]. - The accumulated deficit increased to $576.2 million as of March 31, 2025, compared to $544.2 million at the end of 2024, reflecting a rise of about 5.9%[17]. - The net loss for the three months ended March 31, 2025, was $31.983 million, compared to a net loss of $29.518 million for the same period in 2024, representing an increase of approximately 8.3%[43]. - The basic and diluted net loss per share for the three months ended March 31, 2025, was $(0.43), compared to $(0.58) for the same period in 2024, indicating an improvement in loss per share[43]. - The company reported a net loss of $31.98 million for Q1 2025, compared to a net loss of $29.52 million in Q1 2024, reflecting an increase of $2.47 million[101]. - The company has an accumulated deficit of $576.2 million as of March 31, 2025, and expects to continue incurring net losses for the foreseeable future[110]. - The company expects to continue incurring significant operating losses as it develops NKX019 and other product candidates, with expenses anticipated to increase substantially[139]. Cash and Liquidity - Cash and cash equivalents rose to $52.6 million as of March 31, 2025, compared to $27.9 million at the end of 2024, marking an increase of about 88.8%[17]. - The company had cash, cash equivalents, restricted cash, and investments totaling $351.9 million as of March 31, 2025[31]. - Total cash equivalents as of March 31, 2025, were $51.859 million, up from $27.312 million as of December 31, 2024, indicating improved liquidity[44]. - The company believes its current cash and investments will be sufficient to meet its cash needs for at least the next 12 months[112]. - The company raised $240.1 million in gross proceeds from a public offering, selling 21,010,000 shares at $10.00 each and pre-funded warrants for 3,000,031 shares at $9.9999 each[73]. Operating Expenses - Total operating expenses increased to $36.6 million for Q1 2025, up from $32.8 million in Q1 2024, reflecting a rise of approximately 11.3%[19]. - General and administrative expenses increased to $12.4 million in Q1 2025 from $7.5 million in Q1 2024, primarily due to $5.1 million in severance expenses[102]. - Research and development expenses for Q1 2025 were $24.2 million, slightly down from $25.2 million in Q1 2024, a decrease of about 4.2%[19]. - Research and development expenses for the three months ended March 31, 2025, included direct external development program expenses of $5.420 million, down from $6.593 million in 2024[79]. - The company anticipates substantial increases in research and development expenses related to ongoing clinical trials for drug candidates NKX019 and NKX101[101]. Workforce and Employment - The company announced a reduction in force on March 26, 2025, resulting in a 34% reduction of its workforce, affecting 53 positions[81]. - Severance and other benefits expenses related to the reduction in force totaled approximately $5.4 million, with $5.118 million recognized for employees with no future service requirements[82]. Research and Development - The company operates as a single reporting segment focused on cell therapies for autoimmune diseases, with performance evaluated based on progress in pre-clinical and clinical research objectives[76]. - The company has not generated any revenue from product sales since its inception in 2015 and expects operating expenses to significantly increase as it continues product development[89]. - The company is modifying its clinical trial protocols to include new indications and conditioning regimens for its lead product candidate, NKX019[88]. - The company has invested heavily in developing its intellectual property portfolio and in-house manufacturing capabilities since its inception in 2015[138]. - The company is currently enrolling patients in the Ntrust-1 and Ntrust-2 clinical trials for NKX019, targeting autoimmune diseases[150]. Regulatory and Market Challenges - The FDA has not approved any cell-based therapies for autoimmune diseases, presenting regulatory challenges for the company's product candidates[151]. - The company acknowledges the risks associated with the clinical success of NKX019, which is critical for its business and growth prospects[165]. - The competitive landscape for B-cell mediated autoimmune diseases is intense, with numerous companies developing similar therapies[194]. - The company may face challenges in raising additional funds through equity or debt financing, which could dilute existing stockholder interests[122]. - The company may need to negotiate licenses for terminated product candidates, which could increase expenditures and limit future revenue potential[200]. Future Plans and Expectations - The company plans to finance cash needs through proceeds from secondary offerings and may require additional capital for pivotal trials[147]. - The company plans to pursue accelerated approval pathways for product candidates, which may include seeking designations like Breakthrough Therapy or Fast Track from the FDA[211]. - The company may need to raise additional funds sooner than planned due to unforeseen costs or delays in clinical trials[149].

Financial Performance - USA Rare Earth reported a net income of $51.8 million for Q1 2025, compared to a net loss of $4.5 million in Q1 2024[19] - Adjusted net loss for Q1 2025 was $8.5 million, compared to an adjusted net loss of $4.5 million in Q1 2024[24] - The company reported a revenue of $1.5 billion for Q3 2023, representing a 15% year-over-year increase[26] - The company expects Q4 2023 revenue guidance of $1.7 billion, indicating a 13% growth from Q3 2023[26] - Gross margin improved to 45%, up from 42% in the previous quarter[26] Assets and Cash Flow - Total assets increased to $77.1 million as of March 31, 2025, up from $69.1 million at the end of 2024[17] - Cash and cash equivalents increased to $23.4 million at the end of Q1 2025, up from $16.8 million at the beginning of the year[21] - The company raised over $100 million since the beginning of 2025 to support its business operations[4] Operating Costs and Expenses - Operating costs and expenses for Q1 2025 were $8.7 million, significantly higher than $4.7 million in Q1 2024[19] - Operating expenses increased by 10% due to higher marketing investments[26] Production and Technology - The company produced dysprosium oxide with a purity of over 99% from the Round Top deposit[6] - USA Rare Earth is advancing its processing technologies in Colorado to enhance its rare earth supply chain[4] - The company is focused on establishing domestic rare earth production to meet the growing demand from various industries[14] Customer and Market Expansion - The company signed its first customer MOU for rare earth sintered magnet production scheduled for 2026[6] - New product launches contributed to a 25% increase in sales in the last quarter[26] - Market expansion efforts led to a 30% increase in international sales[26] - The company plans to enter two new markets by the end of 2024, targeting a 15% market share[26] Strategic Initiatives - The company completed a strategic acquisition for $500 million, expected to enhance market share[26] - The company invested $200 million in R&D for new technologies, aiming to enhance product offerings[26] User Growth - User base grew to 10 million active users, a 20% increase compared to the previous quarter[26]

Exhibit 99.1 Battalion Oil Corporation Announces First Quarter 2025 Financial and Operating Results HOUSTON, TEXAS – May 14, 2025 – Battalion Oil Corporation (NYSE American: BATL, "Battalion" or the "Company") today announced financial and operating results for the first quarter of 2025. Key Highlights Management Comments The Company has continued drilling operations as part of its previously announced 2025 six-well activity plan, completing four Monument Draw wells and drilling ahead of schedule on the rem ...